Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 5/20 | 0.51 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.50 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.50 |
| ▸ | DAO | P14920 | 1/20 | 0.49 |
| ▸ | CNR1 | P21554 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.43 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.43 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2095183 | 0.90 | SLC13A5 (0.45) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL27504292 | 0.89 | MAPK14 (0.48) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL1047225 | 0.85 | CHRM2 (0.55) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL2091050 | 0.85 | CETP (0.39) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL27995244 | 0.85 | DAO (0.40) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL5009648 | 0.84 | DAO (0.55) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL178310 | 0.82 | CHRM2 (0.55) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL19062249 | 0.82 | CETP (0.53) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL17288668 | 0.82 | CHRM2 (0.52) | CETPCHRM2CHRM1CHRM3DAO | |
| SCHEMBL3158268 | 0.82 | TACR1 (0.51) | CETPCHRM2CHRM1CHRM3DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 138 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10065926-B2 | Use of substituted dihydrooxindolylsulfonamides, or the salts thereof, for increasing the stress tolerance of plants | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-09-04 | — | — | US | claimed |
| EP-3051946-B1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES OR THEIR SALTS FOR INCREASING STRESS TOLERANCE IN PLANTS | BAYER CROPSCIENCE AG (DE) | 2017-11-29 | — | — | EP | claimed |
| US-20160237035-A1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2016-08-18 | — | — | US | claimed |
| US-20150164854-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEROF | PHARMACYCLICS LLC | 2015-06-18 | — | — | US | claimed |
| WO-2013066833-A1 | COMPOUNDS AND METHODS TO INHIBIT HISTONE DEACETYLASE (HDAC) ENZYMES | GLAXOSMITHKLINE LLC (US) | 2013-05-10 | — | — | WO | claimed |
| US-7960380-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2011-06-14 | — | — | US | claimed |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | PHARMACYCLICS, INC. (US) | 2011-01-27 | — | — | US | claimed |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | claimed |
| US-7723333-B2 | Non-anilinic derivatives of isothiazol-3(2H)-one 1,1-dioxides as liver X receptor modulators | ASTRAZENECA AB (SE) | 2010-05-25 | — | — | US | claimed |
| US-20090270497-A1 | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors | PHARMACYCLICS, INC. (US) | 2009-10-29 | — | — | US | claimed |
| US-7420089-B2 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-09-02 | — | — | US | claimed |
| US-7368476-B2 | Hydroxamates as therapeutic agents | PHARMACYCLICS, INC. (US) | 2008-05-06 | — | — | US | claimed |
| CN-101137628-A | Non-anilinic derivatives of isothiazol-3(2h)-one 1,1-dioxides as liver x receptor modulators | ASTRAZENECA AB (SE) | 2008-03-05 | — | — | CN | claimed |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. (US) | 2008-01-03 | — | — | US | claimed |
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | PHARMACYCLICS, INC. | 2007-12-20 | — | — | US | claimed |
| EP-1838687-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | AstraZeneca AB (SE) | 2007-10-03 | — | — | EP | claimed |
| US-7276612-B2 | For hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides | PHARMACYCLICS, INC. (US) | 2007-10-02 | — | — | US | claimed |
| WO-2006073366-A1 | NON-ANILINIC DERIVATIVES OF ISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AS LIVER X RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2006-07-13 | — | — | WO | claimed |
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | AXYS PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | US | claimed |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AXYS PHARMACEUTICALS, INC. (US) | 2005-08-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293540-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | HDAC3, HDAC1, CDC25C | CETP 3120/4885CHRM2 4390/4885CHRM1 4154/4885 |
| US-10065926-B2 | Use of substituted dihydrooxindolylsulfonamides, or the salts thereof, for increasing the stress tolerance of plants | SQOR, DHPS, QDPR | CETP 4517/4885CHRM2 3005/4885CHRM1 2905/4885 |
| US-20150164854-A1 | FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR AND USES THEROF | HDAC1, HDAC2, HDAC8 | CETP 1355/4885CHRM2 4609/4885CHRM1 4744/4885 |
| US-20090270497-A1 | Treatment of Non-Localized Inflammation with pan-HDAC Inhibitors | HDAC2, HDAC1, HDAC4 | CETP 3346/4885CHRM2 4331/4885CHRM1 4156/4885 |
| US-20050187261-A1 | For hepatitis C; histone deacetylase inhibitors, anticarcinogenic agents; N-hydroxy-4-{[(benzofuran-, benzothiophen-, or indol-)-2-ylcarbonylamino]alkoxy}benzamides; amidation of a benzoic acid, benzoate, benzoyl halide with hydroxyamine | AADAC, HDAC3, HDAC4 | CETP 2537/4885CHRM2 4778/4885CHRM1 4576/4885 |
| US-20110021528-A1 | NOVEL HYDROXAMATES AS THERAPEUTIC AGENTS | HDAC1, HDAC3, HDAC5 | CETP 2677/4885CHRM2 4743/4885CHRM1 4746/4885 |
| US-20100227847-A1 | Non-Anilinic Derivatives Of Isothiazol-3(2H)-one 1,1-Dioxides As Liver X Receptor Modulators | NR1H2, NR1H3, NR1I2 | CETP 129/4885CHRM2 1103/4885CHRM1 1183/4885 |
| US-20160237035-A1 | USE OF SUBSTITUTED DIHYDROOXINDOLYLSULFONAMIDES, OR THE SALTS THEREOF, FOR INCREASING THE STRESS TOLERANCE OF PLANTS | SQOR, DHPS, QDPR | CETP 4517/4885CHRM2 3005/4885CHRM1 2905/4885 |
| US-20050227976-A1 | Novel hydroxamates as therapeutic agents | HDAC1, HDAC5, HDAC10 | CETP 3494/4885CHRM2 4593/4885CHRM1 4722/4885 |
| US-20080004331-A1 | for hepatitis C; histone deacetylase inhibitors; N-hydroxy-4-{[(naphthyl-carbonylamino]alkoxy}benzamides; anticarcinogenic agent; acute promyelocytic leukemia; cell-cycle arrest in late G1 phase or at the G2/M transition | HDAC3, HDAC1, CDC25C | CETP 3120/4885CHRM2 4390/4885CHRM1 4154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.